This episode tries out a different format from our regularly scheduled programming. We sit down and discuss (and sometimes rant about) our thoughts about Gilead's $3k price tag announcement for remdesivir. What was supposed to be a quick discussion of a current event quickly devolved into broader discussions about drug pricing, patent law, and public opinion.

 

email: [email protected]

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx